In achondroplasia, for example, BMN 333 recently began dosing for a first-in-human study, according to BioMarin's earnings report. Like Voxzogo, BMN 333 is a C-type natriuretic peptide ...

The incidence of hypochondroplasia is not known, but it has been estimated to be about as common as achondroplasia, which is seen in around 1 in 15,000 to 40,000 births. BioMarin has said that ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stands ...

BioMarin's highest-potential drug, Voxzogo, launched in late 2021. The drug has shown the ability to restore normal growth rates in young patients with achondroplasia, the most common form of ...

Achondroplasia is a type of dwarfism that affects the growth in children, leading to a short stature or small size. Achondroplasia is a rare genetic condition that affects one in every 15,000 to ...

BioMarin reported noteworthy regulatory advancements, including guidance on achondroplasia screening and extending Voxzogo availability to 47 countries, with ambitions to reach 60 markets by 2027.

led by the continued global expansion of VOXZOGO for achondroplasia…In summary, we expect continued high performance as we benefit from BioMarin's revamped corporate strategy and operating model ...

BioMarin reported a strong quarter, and Voxzogo still has ample room to grow from here, both in terms of greater penetration of the achondroplasia market and in expansion indications longer-term ...

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive and consistent results from multiple real-world evidence studies of VOXZOGO® (vosoritide) in children with achondroplasia.